Windtree’s BNB Treasury Gamble Backfires: Nasdaq Delisting After 77% Stock Collapse

Windtree Therapeutics shares plummeted 77% after receiving a Nasdaq delisting notice for failing to maintain the $1 minimum bid price requirement. The biotech company made headlines in July by becoming the first Nasdaq-listed firm to implement a BNB treasury strategy, announcing plans to purchase up to $200 million worth of the token through agreements with Build and Build Corp.

Initial excitement about the crypto pivot quickly evaporated. The stock, which had briefly rallied on the BNB announcement, crashed to 11 cents following the delisting news. Trading will now move to over-the-counter markets as BNB itself hits new all-time highs—creating a stark contrast with Windtree's deteriorating financial position.

This failed experiment underscores the risks public companies face when venturing into crypto treasury management without established frameworks or proper FSA compliance. While digital assets like BNB continue their bull run, traditional markets show zero tolerance for unproven crypto strategies from financially struggling companies.